Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05001139
Other study ID # ReGl/20/Rec-Der/001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 15, 2021
Est. completion date June 15, 2023

Study information

Verified date September 2022
Source Relife S.r.l.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity. The disease severity will be clinically measured through the Investigator Global Assessment (IGA) after 28 days of treatment.


Description:

The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity, by alleviating the symptomatology. The product will be applied for 42 days of treatment, 2 times per day into the face. The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety of the product


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date June 15, 2023
Est. primary completion date December 29, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject's written informed consent obtained prior to any study-related procedures; 2. Generally healthy male and female aged = 18 years; 3. Presence of atopic dermatitis (AD), irritant contact dermatitis (ICD) or allergic contact dermatitis (ACD) of mild-moderateseverity: ? IGA score 2 (=mild) or 3 (=moderate); 4. Dermatitis affecting one or more body areas (face, legs, arms, etc.); 5. Subjects with cooperative attitude, able to comprehend the full nature and the purpose of the investigation, including possible risks and side effects, and able to comply with the requirements of the entire investigation (including ability to attend the planned visits according to the time limits), based on Investigator's judgement. Exclusion Criteria: 1. Severe dermatitis at inclusion; 2. Pregnant and breastfeeding women; 3. Concomitant other skin disorders including skin infections; 4. Currently or previously diagnosed or treated (chemotherapy and/or radiotherapy) for cancer in the past 5 years; 5. History of previous skin cancer (history of non-metastatic squamous or basal cell carcinoma of the skin is allowed); 6. Active infections or use of antibiotics in the past 7 days; 7. Diabetic subjects; 8. History of congenital or acquired immunodepression; 9. Immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, any typology of lupus, rheumatoid arthritis) which could place the subject at risk or interfere with study results; 10. Use of any topic medication for dermatitis in the past 14 days; 11. Use of any topic product for dermatitis in the 2 days before study treatment start; 12. Any systemic treatment or procedure that could influence dermatitis activity within the past 30 days (or 5 half-lives); 13. Use of any corticosteroids, immunosuppressant drugs or immunotherapy within the past 30 days (or 5 half-lives); 14. Use of oral antihistamines and antidepressants in the past 30 days; 15. Subjects with any other clinically significant or unstable concurrent disease or skin condition or general condition that, in the Investigator's opinion, might interfere with the study evaluations; 16. Allergy, sensitivity or intolerance to the components of the investigational device formulations ingredients; 17. Concomitant or previous participation in other interventional clinical study in the past 3 months; 18. Subjects planning sun exposure or tanning booths or UV sources throughout the course of the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Relizema ecofoam
DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration

Locations

Country Name City State
Italy AOU Policlinico "G. Rodolico- San Marco" Catania Italia

Sponsors (1)

Lead Sponsor Collaborator
Relife S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate and confirm the performance of the Relizema ecofoam in the change of the dermatitis severity, by alleviating the symptomatology. The disease severity will be clinically measured through the Investigator Global Assessment (IGA is based on a five-point scale:
0 = clear
= almost clear
= mild 3= moderate
4 = severe) for dermatitis after 28 days of treatment.
after 28 days of treatment
Secondary to evaluate the performance of the Relizema ecofoam to evaluate the performance of the Relizema ecofoam in the change of dermatitis severity (IGAs based on a five-point scale: 0 = clear
= almost clear
= mild 3= moderate
4 = severe) after 14 and 42 days of treatment;
after 14 and 42 days of treatment
Secondary to evaluate the eczema to evaluate the eczema change through the EASI (Eczema Area and Severity Index Four body regions are considered: head and neck, trunk (including genital area), upper limbs, lower limbs (including buttocks). The percentage of skin affected by eczema in each region is correlated to an area score (0 = 0: no eczema in this region; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%: the entire region is affected by eczema).
A severity score (0 =none, 1 = mild), 2 =moderate or 3 = severe) is then recorded for each of the four regions identified for the following four signs:
1. Redness (erythema, inflammation);2. Thickness (induration, papulation, swelling-acute eczema); 3. Scratching (excoriation); 4. Lichenification (lined skin, prurigo nodules-chronic eczema). ) score
after 14, 28 and 42 days of treatment
Secondary to evaluate the improvement in itching, burning, pain and pruritus at visits to evaluate the change in pain and pruritus at visits, as reported by the subject at visits by VAS (Visual Analogue Scale The subject will be requested to indicate at each visit his/her itching, burning and pain by placing a vertical mark along a 100 mm VAS (Visual Analogue Scale). The rating will be recorded as a distance from the left side of the scale (0 mm) to the mark made by the patient.) after 14, 28 and 42 days of treatment
Secondary to evaluate improvement in the Quality of Life (QoL) of the subject related to his/her dermatitis, to evaluate change in the Quality of Life (QoL) of the subject related to his/her dermatitis, through the DLQI (Dermatology Life Quality Index DLQI is a questionnaire used to measure the impact of skin disease on the quality of life of an affected person. There are 10 questions, covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, treatment. Each question refers to the impact of the skin disease on the patient's life over the previous week.
Each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).
Global score:
0-1 = No effect on patient's life 2-5 = Small effect 6-10 = Moderate effect 11-20 = Very large effect 21-30 = Extremely large effect. The DQLI will be compiled by the subject at each visit.) questionnaire;
after 14, 28 and 42 days of treatment
Secondary to evaluate the subject's adherence to treatment. to evaluate the subject's adherence to treatment, reported on the subject's diary and the product accountability after 14, 28 and 42 days of treatment
Secondary to evaluate the subject's and Investigator's global evaluation of performance of Relizema ecofoam to evaluate the subject's and Investigator's global evaluation of performance of Relizema ecofoam by means of a 7-items scale (where 1 = very much improved, 2 = improved, 3 = minimally improved, 4
= no change, 5 = minimally worse, 6 = worse, 7 = very much worse)
at the end of the study ( day 42)
Secondary to evaluate the subject's overall acceptability of the treatment to evaluate the subject's overall acceptability of the treatment (which takes into account pleasant or unpleasant feeling with the product and the ease of use), performed by means of a 5-item scale (where 1 = very much satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very much dissatisfied) at the end of the study ( day 42)]
See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Recruiting NCT01012453 - A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema N/A
Completed NCT00375713 - Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Phase 3
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Withdrawn NCT04154033 - Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone Phase 2
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Completed NCT02979210 - Infant Fecal Insult Study N/A
Completed NCT02615912 - A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants N/A
Withdrawn NCT01125761 - Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis Phase 3
Withdrawn NCT00746382 - A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM) Phase 2
Terminated NCT00176956 - Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients Phase 3
Completed NCT00801502 - Salmon in Pregnancy Study N/A
Completed NCT00005781 - Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles N/A
Completed NCT05324618 - Tacrolimus Versus Hydrocortisone in Atopic Dermatitis Phase 4
Completed NCT04826471 - Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam N/A
Recruiting NCT06436183 - A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis Phase 2
Recruiting NCT05891743 - Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.